This recombinant monoclonal antibody is designed as a research-grade biosimilar to Ustekinumab-kfce, targeting IL12B (interleukin-12 subunit beta), also known as the p40 subunit. IL12B is a shared component of both interleukin-12 (IL-12) and interleukin-23 (IL-23), two critical cytokines that regulate T-cell differentiation and inflammatory responses. By binding to the p40 subunit, this antibody effectively neutralizes both IL-12 and IL-23 signaling pathways. These cytokines play central roles in the pathogenesis of various immune-mediated inflammatory conditions, including psoriasis, psoriatic arthritis, Crohn's disease, and other autoimmune disorders characterized by aberrant Th1 and Th17 cell responses.
Ustekinumab-kfce is an FDA-approved therapeutic antibody used clinically for treating moderate-to-severe plaque psoriasis and inflammatory bowel disease. This research-grade biosimilar provides investigators with a valuable tool for studying IL-12/IL-23 signaling mechanisms, evaluating inflammatory pathway modulation, investigating autoimmune disease models, and exploring novel therapeutic strategies targeting these cytokine networks in preclinical research settings.
Email: support@cusabio.com
Distributors Worldwide